Eli Lilly and Company (LLY)
Why Is Lilly (LLY) Up 4.5% Since Last Earnings Report?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock?
Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?
Eli Lilly sells two of the most sought-after treatments -- those prescribed for weight management. Mounjaro and Zepbound are driving double-digit earnings growth at the big pharma company.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Eli Lilly stock could reach $1,001 per share, according to a Wall Street analyst from BMO Capital. Tirzepatide sales are off the charts but could be much higher if not for supply constraints.
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
Eli Lilly: Addressing Supply Challenges Should Accelerate Growth
Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limited by the quantities it can produce. Eli Lilly's competitive position in the obesity market is discussed in today's article along with the potential for growth acceleration in 2025 and 2026 versus current expectations for moderating growth rates.
Got $500? 3 Pharma Stocks to Buy and Hold Forever
Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.
3 High-Flying Stocks That Could Soar Even More
Eli Lilly is just getting started with its powerful obesity drug and a loaded pipeline. It's not too late to invest in scorching-hot Novo Nordisk.
Eli Lilly to spend $5.3 billion to boost Zepbound, Mounjaro manufacturing
Eli Lilly & Co. said Friday that it has more than doubled its investment in a Lebanon, Ind., site to boost manufacturing capacity for its popular weight-loss drug Zepbound and diabetes treatment Mounjaro.
Lilly invests further $5.3 bln in new Indiana site as obesity drug demand soars
Eli Lilly said on Friday it has invested another $5.3 billion in its new Lebanon, Indiana manufacturing plant, more than doubling its previous investment, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
Eli Lilly said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to expand the supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro and other medicines in its pipeline. Demand for Zepbound and Mounjaro has far outpaced supply over the last year, spurring shortages in the U.S. and forcing the pharmaceutical giant to invest heavily to scale up its manufacturing.
Eli Lilly to Spend $5.3 Billion to Make More Mounjaro, Zepbound
The outlay to expand an Indiana production site, combined with a previous $3.7 billion commitment, is the largest manufacturing investment in company history.
